Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study

Denosumab discontinuation without subsequent bisphosphonates (BPs) is associated with bone loss and multiple vertebral fractures. Identifying risk factors for bone loss and vertebral fractures after denosumab discontinuation. This retrospective study measured the outcome of 219 women with osteoporosis who discontinued denosumab treatment and received subsequent treatment with zoledronate, other BPs or a selective estrogen receptor modulator...